DySIS Medical Company Profile
DySISmedical is a medical device company that designs, develops, manufactures and markets imaging systems focusing on the non-invasive, in-vivo detection of cancerous and pre-cancerous lesions.
DySISmedical has developed a proprietary technology that has the potential to address a number of diseases affecting millions of people worldwide and costing billions of dollars to healthcare systems.
The first product introduced to the market is DySIS, which assists clinicians with non-invasive, in vivo detection and diagnosis of cancerous and pre-cancerous lesions of the cervix. DySIS provides advanced tools to aid medical practitioners in the detection, grading, and documentation of cervical neoplasia.
DySIS is CE-marked in Europe, and its ability to provide significantly improved performance argues strongly for its adoption as the standard of care in colposcopy.
Vision: To be the global leader in automated optical molecular imaging technologies for medical diagnostic and screening applications.
Mission: DySISmedical is committed to saving lives through the early detection and diagnosis of disease using biophotonic innovations.
Location
Unit 1.15
Alba Innovation Centre
Livingston
EH54 7GA
GB
Contact
Phone: +44 (0)1506 592159
News Articles
Cervical cancer screening product from DySIS Medical recommended by NICE
DySIS Medical Ltd, the medical devices company in female health, announces that the National Institute for Health and Clinical Excellence (‘NICE’) has today published positive diagnostics guidance...
DySIS Medical receives £7.4m of additional funding.
Company gains new investor Edinburgh 15 April 2013: DySIS Medical Ltd, a medical devices company active within women's health, today announces the completion of a £7.4 million (gross)...
DySIS Medical receives £7.4m of additional funding
DySIS Medical Ltd, a medical devices company active within women’s health, today announces the completion of a £7.4 million (gross) fundraising. The investment...
DySIS Cervical Cancer Screening Tool Achieves Clinical and Cost Benefits to Patients
Study commissioned by NIHR HTA programme on behalf of NICE highlights sensitivity and benefits of DySIS over conventional methods Edinburgh – 28 March 2012 - DySIS Medical Ltd, t...
NICE Publishes Positive Draft Guidance on DySIS Cervical Cancer Screening Product
Guidance shows product is cost-effective and clinically robust Edinburgh – 3 April 2012 - DySIS Medical Ltd, the medical devices company in female health, announces that the National Inst...
DySIS Medical Ltd, the medical devices company in female health, announces that the National Institute for Health and Clinical Excellence (‘NICE’) has today published positive...
Cervical cancer screening: an interview with Alastair Atkinson, CEO of DySIS Medical Ltd
Cervical Cancer is a tragic disease. First and foremost, because it is entirely preventable if the early symptoms are detected in a timely manner
Drugs and Medications
None
PubMed Articles
BACKGROUND: Statins reduce cardiovascular events by about one third; thus two out of three events occurring without any lipid lowering treatment still might happen under statin treatment. One reason m...
Clinical Trials
Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation
PCI (optimal catheter-based coronary revascularization) + intensive medical therapy is superior to intensive medical therapy alone using the combined endpoint of all-cause mortality or non...
Does Follow-up With Serum Beta Human Chorionic Gonadotropin (BhCG) Simplify Medical Abortion?
The purpose of this study is to evaluate if BhCG testing to determine the completion of medical abortion simplifies the medical abortion protocol. Investigators hypothesize that women rand...
The Impact of Internationalize Medical Services to localPeople Seeking Medical Care
Recently The Department of Health of Taiwan has launched the "Internationalize Medical Services Flagship Program", expecting to promote Taiwan's high-quality of medical services to the int...
Development and Evaluation of a Medical Intervention for Early Childhood Caries
This study aimed to evaluate the effect of three forms of continuing medical education (CME) on provision of preventive dental services to Medicaid-enrolled children by medical personnel i...
Clinical Evaluation of the Interlace Medical Hysteroscopic Morcellator
This study assesses the effectiveness of intrauterine fibroid and polyp removal using the Interlace Medical 1st generation hysteroscopic morcellator device based on a retrospective review...
Companies
DySIS Medical Ltd has its global headquarters in Edinburgh. The company is committed to saving lives through the early detection and diagnosis of disease using biophotonic innovat...
DySISmedical is a medical device company that designs, develops, manufactures and markets imaging systems focusing on the non-invasive, in-vivo detection of cancerous and pre-cancerous lesions. Dy...
The Medical Affairs Company LLC
The Medical Affairs Company LLC is a full service Contract Medical Organization that provides pharmaceutical, biotechnology, and medical device industry clients a wide array of outsourcing capabil...
Headquartered in Amsterdam, Netherlands, Medical Brands provides consumers with solutions in the OTC to everyday medical problems. Medical Brands develops patents, registers and p...
MedBio Publications provides 5 key services: medical writing, medical editing, medical translation, medical illustration, and medical publishing. Our clients are primarily national and international m...
More Information about "DySIS Medical" on BioPortfolio
We have published hundreds of DySIS Medical news stories on BioPortfolio along with dozens of DySIS Medical Clinical Trials and PubMed Articles about DySIS Medical for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of DySIS Medical Companies in our database. You can also find out about relevant DySIS Medical Drugs and Medications on this site too.
